The most effective treatment for overt symptomatic AD will likely require more than one therapeutic [49], with tau targeting agents being an attractive means to augment anti-Aβ immunotherapy. Nonetheless, recent clinical trials demonstrate that treatment with certain anti-Aβ antibodies is disease modifying [6, 45] raising the prospect that further optimizing this approach may yield even more benefit. Here, MAPT is linked to Alzheimer disease.